• Gain Therapeutics disclosed a poster on long-term open-label data for rexaceract in Parkinson’s disease, scheduled for presentation on Oct. 7, 2026.
• The update covers an extension of its Phase 1b trial, which allows dosing for up to 12 months in patients with or without a GBA1 mutation.
• Earlier Phase 1 results in healthy volunteers have already been reported, showing the oral drug was generally safe and demonstrated biological activity consistent with its target.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609291750PRIMZONEFULLFEED9836484) on September 29, 2026, and is solely responsible for the information contained therein.